Clinical Trial Detail

NCT ID NCT02928224
Title Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (BEACON CRC)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Array BioPharma

colorectal cancer


Cetuximab + Encorafenib

Binimetinib + Cetuximab + Encorafenib

Cetuximab + Irinotecan

Cetuximab + Fluorouracil + Irinotecan + Leucovorin

Age Groups: senior adult

Additional content available in CKB BOOST